Pneumococcal conjugate second or third-dose vaccines (PCVc) in Cyprus
Cyprus: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 83.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Cyprus, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Cyprus is 83.0%, measured in 2025. That is the highest value across all 18 years on record.
That represents a change of up 1.2% on the previous year and up 2.5% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Cyprus peaked at 83.0% in 2025 and was at its lowest, 0.0%, in 2008.
Cyprus ranks 104th of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Cyprus, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 81.0% | — |
| 2016 | 81.0% | +0.0% |
| 2017 | 81.0% | +0.0% |
| 2018 | 81.0% | +0.0% |
| 2019 | 81.0% | +0.0% |
| 2020 | 81.0% | +0.0% |
| 2021 | 81.0% | +0.0% |
| 2022 | 81.0% | +0.0% |
| 2023 | 74.0% | -8.6% |
| 2024 | 82.0% | +10.8% |
| 2025 | 83.0% | +1.2% |
Cyprus compared with similar countries
- Cyprus's 83.0% is below the median for high income countries, which is 91.0%, 91% of the median. (63 countries reporting)
- Cyprus's 83.0% is below the median for Europe & Central Asia, which is 87.0%, 95% of the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 40.5% | 0.0% | 81.0% | 10 |
| 2020s | 80.3% | 74.0% | 83.0% | 6 |
Countries ranked near Cyprus
More health data for Cyprus
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -1.51 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,325 deaths per 1,000 people (2090)
- Number of infants who die before age 1 7 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.0526 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0263 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.0182 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Cyprus?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Cyprus was 83.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Cyprus?
- The highest recorded value was 83.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Cyprus?
- The lowest recorded value was 0.0% in 2008.
- How does Cyprus rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Cyprus ranks 104th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Cyprus?
- Over the last ten years it is up 2.5%. The long-run trend across the full record is volatile.
- Where does this Cyprus data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).